Banoxantrone (dihydrochloride)
Banoxantrone (dihydrochloride) Basic information
- Product Name:
- Banoxantrone (dihydrochloride)
- Synonyms:
-
- Banoxantrone 2HCl
- 1,4-Bis[[2-(dimethyloxidoamino)ethyl]amino]-5,8-dihydroxy-9,10-anthracenedione dihydrochloride
- AQ4N dihydrochloride
- Banoxantrone dihydrochloride >=98% (HPLC)
- 2,2'-((5,8-Dihydroxy-9,10-dioxo-9,10-dihydroanthracene-1,4-diyl)bis(azanediyl))bis(N,N-dimethylethanamine oxide) dihydrochloride , Banoxantrone 2HCl
- 2,2'-((5,8-Dihydroxy-9,10-dioxo-9,10-dihydroanthracene-1,4-diyl)bis(azanediyl))bis(N,N-dimethylethanamine oxide) dihydrochloride
- Banoxantrone dihydrochloride (AQ4N), Topoisomerase II inhibitor
- Banoxantrone dihydrochloride, 10 mM in DMSO
- CAS:
- 252979-56-9
- MF:
- C22H29ClN4O6
- MW:
- 480.95
- Mol File:
- 252979-56-9.mol
Banoxantrone (dihydrochloride) Chemical Properties
- storage temp.
- Store at -20°C, protect from light, stored under nitrogen
- solubility
- Soluble to 50 mM in water and to 25 mM in DMSO
- form
- Solid
- color
- Blue to dark blue
- Water Solubility
- Water : 25 mg/mL (48.32 mM)
Banoxantrone (dihydrochloride) Usage And Synthesis
Uses
Banoxantrone (AQ4N) is a hypoxia-activated prodrug of topoisomerase II inhibitor AQ4 (Bioreductive AQ4 precursor). studies have shown that its has also exhibited anti-tumor efficacy in vivo when combined with oxic cell cytotoxins.
Biological Activity
Banoxantrone (AQ4N) is a hypoxia-activated prodrug of topoisomerase II inhibitor AQ4 (Bioreductive AQ4 precursor).', 'Banoxantrone dihydrochloride enhances the anti-tumor effect caused by radiation.
in vivo
Banoxantrone (200 mg/kg) significantly enhances the tumor growth delay caused by radiation. This occurred when radiation is administered both as a single dose (12 Gy) and in a multifraction regimen (5x3 Gy). A study of the scheduling of Banoxantrone (AQ4N) administration shows that there is a very long time period over which a maximal effect can be elicited (drug given 4 days before to 6 h after radiation). These results suggest that Banoxantrone has significant potential as a bioreductive drug[1]. The activation of banoxantrone cytotoxicity in vivo requires tumor hypoxia that is more extensive or prolonged than can readily be achieved by vasodilation or by antiangiogenic drug treatment[2]. Incorporation of banoxantrone into conventional chemoradiation protocols therefore targets both oxygenated and hypoxic regions of tumors, and potentially will increase the effectiveness of therapy. A single dose of 60 mg/kg banoxantrone enhances the response of RT112 (bladder) and Calu-6 (lung) xenografts to treatment with cisplatin and radiation therapy. Banoxantrone will increase the efficacy of chemoradiotherapy in preclinical models[3].
IC 50
Topoisomerase II
storage
Store at +4°C
Banoxantrone (dihydrochloride)Supplier
- Tel
- 025-83697070
- info@chemlin.com.cn
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Tel
- 021-58955995
- sales@medchemexpress.cn
- Tel
- 15221275939
- shenlinxing@macklin.cn
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com